Reviewed Mar 2026 | PubMed sources
Active Market
Netherlands is selected. The evidence comparison is still valid, but provider availability, legal positioning, and cost assumptions may still be staged for later rollout.

Sermorelin vs Tesamorelin: Head-to-Head Comparison

Both are GHRH analogs but tesamorelin is FDA-approved and has Phase III data for visceral fat reduction. Sermorelin was previously FDA-approved for pediatric use and is widely prescribed off-label in anti-aging clinics. Tesamorelin is more potent but substantially more expensive.

Approved Comparison Routing

Approved options in this comparison

A
Sermorelin

Sermorelin is currently modeled on this site as an approved treatment path for: Diagnosis and treatment of growth hormone deficiency in children. Brand names in the current dataset: Geref.

A
Tesamorelin

Tesamorelin is currently modeled on this site as an approved treatment path for: Reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Brand names in the current dataset: Egrifta, Egrifta SV.

Validation note: This block reflects the site's current structured treatment data and internal routing logic. It does not replace checking current labeling, payer rules, or local prescribing conditions.

Need help choosing between prescribing paths?

One or more options in this comparison are currently modeled on this site as approved treatment paths. Use the provider matcher to narrow the best next step based on your budget, insurance, and timeline.

Join provider rollout

Side-by-Side Comparison

DimensionSermorelinTesamorelin
Evidence LevelFormerly FDA-approved; extensive clinical usePhase III trials; currently FDA-approved
FDA StatusPreviously approved (withdrawn commercially)Currently FDA-approved (Egrifta)
MechanismGHRH(1-29) analogModified GHRH analog with enhanced potency
Primary UseGH deficiency, anti-agingHIV lipodystrophy, visceral fat reduction
Half-Life~10-20 minutes~26-38 minutes
Side EffectsFlushing, headache, injection painArthralgia, injection site reactions, edema
CostLow to moderate (widely compounded)Very high (brand-name pharmaceutical)
Evidence Level
Sermorelin
Formerly FDA-approved; extensive clinical use
Tesamorelin
Phase III trials; currently FDA-approved
FDA Status
Sermorelin
Previously approved (withdrawn commercially)
Tesamorelin
Currently FDA-approved (Egrifta)
Mechanism
Sermorelin
GHRH(1-29) analog
Tesamorelin
Modified GHRH analog with enhanced potency
Primary Use
Sermorelin
GH deficiency, anti-aging
Tesamorelin
HIV lipodystrophy, visceral fat reduction
Half-Life
Sermorelin
~10-20 minutes
Tesamorelin
~26-38 minutes
Side Effects
Sermorelin
Flushing, headache, injection pain
Tesamorelin
Arthralgia, injection site reactions, edema
Cost
Sermorelin
Low to moderate (widely compounded)
Tesamorelin
Very high (brand-name pharmaceutical)

Peptide Overviews

Sermorelin

AFDA Approved

Sermorelin is the shortest fully functional fragment of GHRH (amino acids 1-29). It was the first GHRH analog approved by the FDA, marketed as Geref for diagnostic and therapeutic use. Geref was subsequently discontinued in the U.S. market, though sermorelin remains available through compounding pharmacies. Geref was subsequently discontinued in the U.S. market, though sermorelin remains available through compounding pharmacies.

Growth Hormone SecretagoguesFDA Approved
View full Sermorelin profile →

Tesamorelin

AFDA Approved

Tesamorelin is a synthetic GHRH analog approved by the FDA as Egrifta for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

Growth Hormone SecretagoguesFDA Approved
View full Tesamorelin profile →

GLP-1 Support Essentials

Products that can support side-effect management, hydration, and protein intake.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Recommended Reading

Books covering peptide science, longevity research, and biohacking frameworks.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Sermorelin vs Tesamorelin: FAQ